8X Ventures

8X Ventures is a Chennai-based deep-tech VC investing in foundational scientific innovations, with an explicit interest in molecular diagnostics, life sciences tools, and AI/ML applied to biological problems. The firm operates across pre-seed through Series A with checks generally in the $250K to $1M range, which positions it as a science-friendly first institutional partner rather than a Series A lead. The portfolio includes companies like D-Nome in molecular diagnostics, which is a useful signal for what kind of risk and timeline the team is comfortable underwriting. This is not a digital health or telehealth investor; it is a fund that takes science seriously and is willing to back PhD-led teams pursuing platform technologies that will take years to commercialize. The right founder profile is a scientist or scientist-engineer team with genuine technical depth in genomics, proteomics, diagnostics chemistry, life sciences instrumentation, or AI-for-biology, ideally with an academic anchor at IISc, IITs, or top-tier research institutions, and a clear path to a defensible IP position. The wrong fit is a workflow software company, a B2C wellness brand, or a clinical-services aggregator. The right entry path is through the Indian deep-tech founder community, through co-investors like Speciale Invest with whom 8X frequently overlaps, or through introductions from the academic research ecosystem in Bengaluru, Hyderabad, and Chennai. The team is reachable through targeted outreach when the science is strong enough to merit attention, but warm referrals materially compress the diligence timeline. When pitching, lead with the science and the technical moat: what the platform does that incumbent technologies cannot, what experimental validation already exists, and which regulatory pathway the company will pursue. Then connect that to a credible commercial trajectory, which for diagnostics means a clear payer or provider customer, and for life sciences tools means a defined end-market in pharma R&D or clinical labs. Caveats: 8X is a small fund and will not solve a $10M Series A on its own, so founders need to plan their syndicate. The firm’s portfolio is still maturing, so external validation through follow-on rounds led by larger life sciences specialists will be the eventual proof point. Use 8X as a credible early science partner with patience for long timelines, paired with operator advisors who can help on commercialization later.